0001178913-22-001179.txt : 20220321 0001178913-22-001179.hdr.sgml : 20220321 20220321060252 ACCESSION NUMBER: 0001178913-22-001179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220314 FILED AS OF DATE: 20220321 DATE AS OF CHANGE: 20220321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Marvin Donald CENTRAL INDEX KEY: 0001891264 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38807 FILM NUMBER: 22754126 MAIL ADDRESS: STREET 1: 2094 LOST CANYON RANCH CT CITY: CASTLE ROCK STATE: CO ZIP: 80104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chemomab Therapeutics Ltd. CENTRAL INDEX KEY: 0001534248 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813676773 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 BUSINESS PHONE: 972-77-331-0156 MAIL ADDRESS: STREET 1: KIRYAT ATIDIM, BUILDING 7 CITY: TEL AVIV STATE: L3 ZIP: 6158002 FORMER COMPANY: FORMER CONFORMED NAME: Anchiano Therapeutics Ltd. DATE OF NAME CHANGE: 20180906 FORMER COMPANY: FORMER CONFORMED NAME: BioCancell Ltd. DATE OF NAME CHANGE: 20111104 4 1 ownership.xml X0306 4 2022-03-14 0 0001534248 Chemomab Therapeutics Ltd. CMMB 0001891264 Marvin Donald 2094 LOST CANYON RANCH CT CASTLE ROCK CO 80104 0 1 0 0 Executive VP, CFO & COO American Depositary Shares 2022-03-14 4 P 0 250 4.00 A 250 D American Depositary Shares 2022-03-14 4 P 0 250 3.98 A 500 D American Depositary Shares 2022-03-14 4 P 0 250 3.90 A 1000 D American Depositary Shares 2022-03-14 4 P 0 250 4.10 A 1250 D American Depositary Shares 2022-03-14 4 P 0 250 4.20 A 1500 D Option to Purchase American Depositary Shares 9.77 2021-11-08 4 A 0 196875 0 A 2021-11-08 American Depositary Shares 196875 196875 D Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only. The options vest and become exercisable over a period of four (4) years, with one quarter (1/4) of the options vesting on November 8, 2022 -- the first anniversary of the grant date -- and the remainder in equal amounts over the ensuing 36 monthly periods, subject to the Reporting Person's continued service. /s/ Matthew Rudolph, Attorney-in-Fact for Donald Marvin. 2022-03-21